Please ensure Javascript is enabled for purposes of website accessibility

2 Risks Facing Merck Today

By Brian Orelli, PhD - Nov 12, 2012 at 9:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Is this pharma stalwart navigating through choppy waters?

Merck (MRK 0.21%) is one of the oldest pharmaceutical companies on the planet -- but history counts for little in an industry perennially fueled by new innovations and scientific breakthroughs. This pharma titan is confronting a number of challenges as the patents for its major drugs expire and new blockbusters become increasingly difficult to discover.

In our brand new premium report on Merck, our senior biotech analyst walks you through the opportunities, threats, and compelling reasons to both buy and sell this stock. Here is just a small excerpt from the full research report:

The biggest risks facing Merck today

  • Vioxx 2.0

    Drug candidates failing while in clinical trials is painful, but discovering that something is wrong after the drug is already on the market is much worse. Not only do you lose a blockbuster (versus just a theoretical blockbuster for a pipeline failure), but getting pulled off the market for safety reasons will inevitably lead to lawsuits. Merck settled Vioxx patient lawsuits for $4.85 billion and settled a lawsuit with the government for $950 million.

    In general, there's little that investors can do to predict major blowups after drugs are on the market. Phase 3 trials are designed to catch most issues, but they're not large enough to illuminate issues that might only show up when a large number of patients start taking the drug.

    The only thing investors can do is realize it's a possibility, reduce their risk by not making any one drugmaker a major part of their portfolio, and make sure that the potential returns justify the risk.
 
  • Early generic competition

    Drug sales fall off a cliff after generic drugs come on the market. That's just a fact of life for drug developers. But at least when generics enter the market after a patent expires, investors can see it coming and adjust their valuations accordingly. The bigger risk is when generic-drug makers are able to invalidate patents, shortening the life of a drug unexpectedly.

    Merck is in various stages of litigation over patents covering AzaSite, Cancidas, Emend for Injection, Nasonex, Nexium, Noxafil, Vytorin, and Zetia.

    The last two are clearly the most troublesome since they're the third and fifth best-selling drugs, respectively, and will soon move up the ranks as Singulair sales fade. A couple of generic-drug makers have sued Merck over the patents on Vytorin and Zetia: Teva Pharmaceuticals (TEVA -0.53%), Impax Laboratories (IPXL), Glenmark Pharmaceuticals, and Actavis.

    The Mylan (MYL) lawsuit is the most advanced at this point and will likely determine whether generic drugs enter the market before December 2016. Mylan lost its first decision, but is appealing the decision to a higher court.

    The problem for investors is that it's really hard to predict how these lawsuits will end. The same caveats in the section about post-approval safety issues also apply.

We hope you enjoyed this sneak peek at our new premium research report on Merck. To get more in-depth information on this stock, click here today to learn more.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$94.03 (0.21%) $0.20
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$8.40 (-0.53%) $0.04
Viatris Inc. Stock Quote
Viatris Inc.
MYL
Impax Laboratories, Inc. Stock Quote
Impax Laboratories, Inc.
IPXL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.